Sporadic AD familial AD etiology environmental factors, genetic predisposition etiology oligomerization of A 42 and initial (diffuse) A 42 deposits subtle.

Slides:



Advertisements
Similar presentations
Clash Of The Titans! Convergence Of Tau And Alpha-Synuclein Amyloid In Neurodegenerative Diseases John Q. Trojanowski, M.D., Ph.D. Institute on Aging Center.
Advertisements

Parkinson’s disease: February 19th BIOS E108 Parkin and PINK1
Etiopathogenesis of Alzheimer's disease
ALS Research Yesterday, Today and Tomorrow Heather D. Durham, PhD.
MITOCHONDRIAL DISEASES
ALZHEIMER’S DISEASE Erin Dancey. Overview Alzheimer’s is the most common cause of dementia in adult life and is associated with the selective damage of.
September 13th BIOS E108 Parkinson’s disease (PD) -Pathology -Diagnosis -  -synuclein.
Parkinson’s Disease Pathology 430/826 The Molecular Basis of Disease Neurological Genetics 9 th March 2015 Dr. John Rossiter
Sorting Through the Tangles: Alzheimer’s Disease
Alzheimer’s Disease Find group of ~4 students ~ 10 minutes Discuss the following personal family connection to AD (if willing only) observations/experiences.
Disorders caused by pathological conformation of proteins
Lewy Bodies in PD. Lewy Body Inclusions and the effect of coffee and decaffeinated extracts on Drosophila neuronal cultures.
Dr. Amr Moustafa Biochemistry Unit Department of Pathology.
Chapter 21. Molecular Mechanisms of Neurological Disease Copyright © 2014 Elsevier Inc. All rights reserved.
Degenerative Diseases of Brain. Degenerative Diseases Spontaneous, progressive degeneration of neurons Sporadic, Familial Overlapping features.
Introduction to Degenerative Brain Diseases
February 12th BIOS E108 Parkinson’s disease (PD) -Pathology -Diagnosis -  -synuclein.
Parkinson’s Disease superKAT :).
VIII. NEURODEGENERATIVE DISEASES. - Are disorders characterized by the cellular degeneration of subsets of neurons that typically are related by function,
Introduction Alzheimer’s disease (AD) is a neurodegenerative disease associated with brain shrinkage and the loss of neurons, particularly cholinergic.
PATHOLOGIC AGGREGATION OF THE BRAIN PROTEIN  -SYNUCLEIN CAUSES CELL DEATH IN PARKINSON AND ALZHEIMER DISEASE, Wenbo Zhou, PhD and Curt R. Freed, MD Division.
Dr. Usman Ghani CNS Block.  Pathophysiology of alzheimer’s disease: 5I.
Molecular Biology and Genetics of Amyotrophic Lateral Sclerosis Michael Sidel February 13, 2008.
Molecular Integration of CNS Neurodegenerative Dementias Christine Van Broeckhoven VIB8 - Department of Molecular Genetics IBB – Laboratory of Neurogenetics.
Mounting Evidence that Endocytosis Regulates  -Synuclein Degradation Jaime Pérez Pineda Advanced Cell Biology Fall 2009.
Cell death in PD: the case for mitochondria. Background defects in the capacity of the ubiquitin-proteasome system (UPS) to degrade unwanted proteins.
D E M E N T I A Q: What other types of dementia are there? Q: What other types of dementia are there? Q: Do they have the same pathophysiology as Alzeimer.
Alzheimer’s Disease Gavin Mast, Musa Abdus-Samad, Arash Rezaeian, Sarah Rocha PHM142 Fall 2015 Instructor: Dr. Jeffrey Henderson.
Mitochondrial function in Cell death in PD. Pathology Loss of SN pigmented dopamine neurons Lewy bodies Lewy neurites-multiple brain regions Lewy bodies.
Under the supervision of miklós jászberényi
Clinical Features Huntington’s disease is a rapidly progressive neurodegenerative disease that leads to dementia. Typically presents with alterations.
Α-synuclein transgenic mouse models of Parkinson’s disease Michelle Maurer December 2015.
By: London Seigle & Marlinda Reakes. Structure of Cytoskeleton  Long, twisted strands (criss-crossing)  A cellular, scaffolding structure  Found within.
Pathogenesis and pathology of parkinsonism
Genetic aspects of Alzheimer disease Karolina Pesz, Błażej Misiak, Maria M. Sasiadek Department of Genetics Wroclaw Medical University, Poland.
Biochemistry of neurodegenerative diseases and prions Alice Skoumalová.
Sapana Shinde, Aaron Ripley, Dr. Sok Kean Khoo MicroRNA expression studies in rotenone- induced cellular model for Parkinson’s disease Department of Cell.
Parkinson’s Disease.
Preston Ge Institute for Cell Engineering
The ageing brain Volume reduction: begins around 50 with a loss of brain weight of around 2-3% per decade Changes in nerve cell numbers and size - various.
CLINICAL CORRELATIONS
Are There Common Mechanisms in Neurodegeneration?
Degenerative brain disease
Syed H. Omar, Christopher J. Scott, Adam S. Hamlin, Hassan K. Obied 
Alzheimer’s Disease Dr. Usman Ghani CNS Block.
Alzheimer’s Disease CNS Block.
III. Parkinson Disease.
Alpha-synuclein in Parkinson's disease
Degenerative Disorders
Nat. Rev. Neurol. doi: /nrneurol
Figure 2 ER stress and proteostasis in neurodegenerative diseases
New Animal Models for Parkinson's Disease
Acetylation Unleashes Protein Demons of Dementia
ALS disease pathology and proposed disease mechanisms.
Probing the Biology of Alzheimer's Disease in Mice
Mechanisms of Neuronal Degeneration in Alzheimer's Disease
Nat. Rev. Neurol. doi: /nrneurol
Parkinson's Disease Neuron
The Role of Apolipoprotein E in Alzheimer's Disease
Selective Neuronal Vulnerability in Neurodegenerative Diseases: from Stressor Thresholds to Degeneration  Smita Saxena, Pico Caroni  Neuron  Volume 71,
Mechanisms Underlying Inflammation in Neurodegeneration
The Ubiquitin Proteasome System in Neurodegenerative Diseases
מחלת אלצהיימר: עבר, הווה ועתיד
Genetic Animal Models of Parkinson's Disease
Alzheimer Mechanisms and Therapeutic Strategies
Alzheimer’s Disease Dr. Usman Ghani Neuropsychiatry Block.
Introduction to degenerative brain disease
PD-associated gene products and their prospective sites of cellular function PD is hypothesized to be a consequence of the dysfunction of intersecting.
Neurodegenerative Tauopathies
Neurodegenerative disease models
Presentation transcript:

sporadic AD familial AD etiology environmental factors, genetic predisposition etiology oligomerization of A 42 and initial (diffuse) A 42 deposits subtle effects of soluble A 42 oligomers on synaptic function inflammatory responses (microglial and astrocytic activation) and amyloid plaque formation progressive synaptic/neuritic injury altered neuronal ionic homoeostasis & oxidative injury aberrant oligomerization and hyperphosphorylation of tau widespread neuronal dysfunction and cell death associated with neurotransmitter deficits dementia and neurodegeneration increase in total A production or increase in the A 42/40 ratio subtle changes in A production or clearance mutations in APP or presenilin pathophysiological alterations Fig. 1A chromosome 17-linked FTLD

Tauopathies tau-positive mutations in tau cause expression of splice variants or missense mutants affect microtuble binding capacity pathophysiological alterations Fig. 1B Chromosome 17-linked FTLD tau pathology TDP-43 proteinopathies tau-negative, ubiquitin-positive etiology loss of a trophic/protective function TDP-43 pathology cause nonsense mediated PGRN mRNA decay reduced secretion of PGRN missorting of PGRN and degradation impaired axonal transport mutations in progranulin neuropathology

sporadic PD familial PD etiology largely unknown environmental factors genetic predisposition degeneration of dopaminergic neurons in the substantia nigra pathophysiological alterations etiology mutations in PD-associated genes autosomal dominant autosomal recessive -synuclein LRRK2 parkin PINK1 DJ-1 oxidative stress mitochondrial dysfunction protein misfolding Fig. 1C

Prion diseases PrP Ctm PrP PrP HD cytoPrP PG14PrP PrP Sc neurodegeneration infectious prions neurodegeneration etiology sporadic inherited acquired mutations Fig. 1D

Gain of function Loss of function neurotoxic signaling PrP synaptic deficits tau, A, PrP impairment of axonal transport tau pore formation -synuclein defective cellular trafficking -synuclein impairment of proteasomal or lysosomal degradation PrP, -synuclein impairment of synaptic dynamics -synuclein increased vulnerability to stress parkin, DJ-1 loss of trophic support progranulin mitochondrial dysfunction PINK1, parkin neuronal dysfunction and cell death Fig. 2